The findings of this multi-center observational study underscore the promising potential of SGLT2 inhibitors (dapagliflozin and empagliflozin) in active cancer patients with HF, including those with cancer therapy-related cardiac dysfunction (CTRCD). Here, SLC5A2 is linked to hydrops fetalis.